News | Current News

Pfizer Acquires BioRexis Pharmaceuticals
Anthem is pleased to announce that Pfizer has entered into an agreement to acquire BioRexis Pharmaceutical Corporation.

Anystream Raises $7 Million Series C
Anystream has closed a $7 million Series C round from Anthem Capital Management, SoftBank Capital and SCP Partners to accelerate the expansion and product offerings of its Anystream Media and Education businesses.

Ion Healthcare raises $5 million Series A Investment
Ion Healthcare, a leading a disease management healthcare company for patients with sleep apnea and breathing disorders has closed a $5 million Series A round of financing from Anthem Capital and Harbert Venture Partners.

Chorus Secures $9 Million in Funding and Announces New CEO
Chorus Systems, the leading developer of management solutions to automatically detect, diagnose and resolve desktop and server-related problems, announced that it has raised $9 million from a syndicate of investors including Anthem Capital Management and has hired John Prisco as CEO.

Anthem invests in Anystream’s $10 Million Series B Round
Anystream, a leading supplier of digital media production and distribution software has closed a $10 million Series B round of financing from Anthem Capital, SOFTBANK Capital Technology Fund and SCP Private Equity Partners.

Immune Control Raises $11.3 Million Series A
Immune Control, an early-stage drug discovery and development company has closed an $11.3 million Series A round of financing from Anthem Capital, Quaker BioVentures, Domain Associates and NewSpring Capital.

Anthem Leads $3.25 Million Series A Investment in Microplate Automation
Microplate Automation Inc. announced that it has raised $3.25 million in a Series A private equity financing led by Anthem Capital Management.

Nucleonics Raises $49.2 Million Series B Round
Qovia, Inc., a rapidly-growing VoIP software company, announced today that it has closed a $10.6 Million Series B round of financing from Anthem Capital, Canaan Partners, Nokia Venture Partners, and Maryland DBED.

Immunicon Issues Initial Public Offering of 6 million Shares
Immunicon announced that it has priced its initial public offering of 6,000,000 shares of its common stock at $8.00 per share.

BioRexis Completes $30 Million Series B Financing
BioRexis Pharmaceutical Corporation announced today that it has raised $30 million in a Series B private equity financing from Anthem Capital Management, Prism Venture Partners, Quaker BioVentures, Johnson & Johnson Development Corporation, Gund Investment Corporation, ProQuest Investments and Tullis-Dickerson.

Biotech stock deals top $100M
Last week, Immunicon Corp. of Huntingdon Valley completed the second-largest biomedical private-stock placement this year when it raised $25 million from a consortium of investors.

Cancer Diagnostics Firm Immunicon Gets $25M Round Four
Immunicon, a biomedical company focusing on the development and comercialization of cell-based diagnostic and related products, announced it has raised $24.8 million in what the company is calling its Series F-2 financing, its fourth institutional financing round.

Defywire Raises $4.5M Series A Round
Attracted by Partnerships with webMethods, Sun Microsystems and Sharp Elctronics, Intersouth Partners and Anthem Capital Lead Investment in Premier Enterprise Mobility Provider.

Rockville biotech experiments with drugs
GlycoMimetics, a company founded to research the science of carbohydrate-protein interactions to advance human health, advanced its own health by securing $4.3 million in its first round of venture capital funding.

GlycoMimetics Gets $4.3 Million Series A Round
GlycoMimetics, a developer of small molecule drugs that mimic the action of carbohydrates, announced that it has raised $4.3 million in a Series A financing, its founding round.

Solstice Software Secures $3.8 Million in Series B Funding
Leading investors Core Capital Partners and Anthem Capital Management fund behind-the-screens testing to radically reduce time, money spent on web services, EAI and complex integration projects.

Life-sciences firms took the spotlight
Local venture capitalists remained an upbeat lot through 2002, despite a slow market for fund-raising and investing.

Anthem swims against VC tide
Anthem Capital Management sailed against the prevailing investment wind well enough to close on its second venture.

New Enterprise and Anthem Capital invest in biotech firm
Two Baltimore venture capital firms invested in a Maryland biotech company that is developing a monitoring device for diabetes patients.

Sensors for Medicine and Science Gets $15M Series C
Sensors for Medicine and Science, which develops sensor technology for the detection and measurement of molecules, announced that it has received $15 million in an ongoing Series C funding round that will close next year with a total of $30 million.

BusinessWeek: On the Trail of Tumor Cells
Scientists at the closely held Immunicon Corp., based in Huntingdon Valley, Pa., think they can take advantage of the shedding process of solid tumors to provide an early warning on cancer.